44results about How to "Inhibit autophagy" patented technology

The invention provides application of brown algae oligosaccharide or pharmaceutically acceptable salt thereof in preparation of a medicine for treating acute kidney injury, wherein the brown algae oligosaccharide is brown algae disaccharide, brown algae triose and / or brown algae tetraose. The invention also provides application of the brown algae oligosaccharide or the pharmaceutically acceptable salt thereof in preparation of medicines for preventing acute kidney injury from being converted into chronic kidney diseases. After the brown algae oligosaccharide is used for treating an animal with acute kidney injury, the serum creatinine level is obviously reduced, the urine concentration function of the kidney is obviously recovered, the levels of renal tubular injury factors (KIM-1 and NGAL) are obviously reduced, the expression of inflammatory factors is obviously reduced, the pathological change of the kidney is obviously improved, and the treatment effect is enhanced along with the increase of the dosage. Therefore, the brown algae oligosaccharide disclosed by the invention has a relatively strong effect of treating the acute kidney injury. In addition, when acute kidney injury occurs, the brown algae oligosaccharide disclosed by the invention can be used for protecting kidney functions and preventing the acute kidney injury from being converted into chronic kidney diseases.

A method for inhibiting the autophagy of motor neurons in a subject is provided. The method comprises administrating to the subject an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound and combinations thereof:wherein A is a C1-C5 alkyl optionally having one or more unsaturated bonds and optionally being substituted by one or more substituents selected from a group consisting of —OH, ═O and C1-C3 alkyl; X is H, —OH,Y is O or S and can optionally combine with A to form a five-membered ring; and R1 is H or a substituted or unsubstituted C1-C20 alkyl, wherein one or more —CH2— of the C1-C20 alkyl are optionally being replaced by —NH— or —O—.

Provided herein are recombinant peptides useful for inhibiting the function of autophagy-related 8 (Atg8) proteins. The recombinant peptides can be used in the preparation of imaging agents for monitoring autophagy in a cell or subject and treating autophagy related diseases, such as cancer.

The invention discloses a cell autophagy inhibitor with Rubiaceae type cyclic peptide as an active ingredient, especially for inhibiting KRAS mutation, especially KRAS-dependent tumor cell protective autophagy, and promoting tumor cell apoptosis; The inhibitor is preferably a nano-micelle injection, which can be applied to the preparation of drugs for treating and preventing KRAS-related cancers, including colon cancer, rectal cancer, lung cancer and pancreatic cancer. The autophagy inhibitor described in the present invention can effectively inhibit the protective autophagy of tumor cells. Its active ingredient Rubiaceae type cyclic peptide has a wide range of sources, its extraction process is mature, and its dosage forms and medication methods are diversified. It can be applied to the treatment of KRAS-related cancers. Treatment and prevention have broad clinical application prospects.

The invention discloses an application of ligustilide as an adjuvant drug of antitumor drugs. The research found that ligustilide can directly inhibit autophagy and then can perform combined effects with the antitumor drugs such as tamoxifen, cis-platinum and the like, the antitumor effect is improved, and the drug resistance of tumor cells to the antitumor drugs can be improved.

The invention relates to a medical configuration item, and particularly relates to a chronic cyclosporin A nephrotoxicity prevention and treatment pharmaceutical composition, the pharmaceutical composition comprises an effective component and a pharmaceutical acceptable auxiliary material, the effective component is an aqueous extract prepared from the following medicinal raw materials by weight: 26-30% of fructus rosae laevigatae, 20-25% of emblic leafflower fruit, 12-15% of fruit of Chinese magnoliavine and 30-40% of gynostemma pentaphylla. The chronic cyclosporin A nephrotoxicity prevention and treatment pharmaceutical composition has remarkable effect on chronic cyclosporin A nephrotoxicity prevention and treatment.

The present invention discloses new uses of 3,4-fragmented cyclic altine-type triterpenoids, the compounds are black schisandrin or southern schisandra, including for preparing autophagy inhibitor, preparing for increasing antitumor drug treatment A sensitive drug, the compound can inhibit the ubiquitination modification of autophagy receptor p62, prevent the activation of p62 autophagy receptor function, and can inhibit the protective autophagy of tumor cells induced by anti-tumor drugs, and the present invention also provides An anti-tumor drug composition, including 3,4-fragmented cyclic altine-type triterpenoids and anti-tumor drugs that easily induce tumor cell protective autophagy, can inhibit tumor cell growth and promote tumor cell death, and can be used for Treatment of cancers such as breast cancer.

The invention provides new application for a lycorine and bortezomib composition medicine. The lycorine and bortezomib composition is used for preparing a medicinal preparation for treating multiple myeloma. Compared with the fact that lycorine and bortezomib are used separately, combined use of lycorine and bortezomib can realize a better cell proliferation inhibition effect, and cell autophagy can be inhibited through combined use. The composition greatly improves sensibility of multiple myeloma to bortezomib and is applicable to drug-resistant multiple myeloma which is difficult to treat.

The invention discloses an application of seneciphylline in preparation of antitumor medicines. The seneciphylline can inhibit HeLa cell proliferation and induce HeLa cell autophagy in a dose dependent and a time dependent manner. In addition, the seneciphylline inducing the HeLa cell autophagy is depended on activation of MEK / ERK1 / 2 pathway. The invention provides a novel treatment medicine of treating human cervical cancer.